Alzamend, an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, announced that it contracted with Altasciences Clinical Kansas and iResearch Atlanta, LLC to manage and conduct, respectively, its Phase IIA multiple ascending dose (“MAD”) study in patients with mild to moderate Alzheimer’s Disease. The Phase IIA Study, which is expected to commence enrollment in May 2022, is for the purposes of evaluating the safety and tolerability of AL001 under multiple-dose, steady-state conditions, and to determine the maximum tolerated dose in patients with mild to moderate Alzheimer’s. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer’s. AL001 has the potential to deliver the clinical benefits of marketed lithium carbonate but with reduced risk of side effects.
We believe AL001 could potentially provide clinicians with a major improvement over current lithium-based treatments and may constitute a means of treating Alzheimer’s and other neurodegenerative diseases and psychiatric disorders.